This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

Repaglinide was initially approved by the United States Food and Drug Administration (FDA) in December 1997.

A 2003 study evaluated the safety and effectiveness of repaglinide in patients with type 2 diabetes. The study found that repaglinide effectively lowered HbA1c levels and improved glycemic control while presenting a relatively low risk of hypoglycemia. The study also demonstrated that repaglinide is safe for use in patients with varying degrees of renal impairment.

Mechanism of Action of undefined

Repaglinide reduces blood glucose levels by stimulating the pancreas to release insulin. This effect relies on the presence of functioning beta (β) cells in the pancreatic islets. The release of insulin depends on glucose levels and decreases when glucose concentrations are low. 

Repaglinide binds to specific sites on ATP-dependent potassium channels in the β-cell membrane, causing these channels to close. This closure depolarises the β-cell and opens calcium channels, which results in an increased influx of calcium and stimulating insulin secretion. 

This ion channel mechanism selectively targets pancreatic tissue and has a low affinity for the heart and skeletal muscle.

Uses of undefined

Repaglinide is indicated for adults with type 2 diabetes mellitus when diet, weight reduction, and exercise no longer control their hyperglycemia satisfactorily. It is recommended for adults with type 2 diabetes mellitus who show no improvements when treated with metformin alone.

undefined Drug administaration and Dosage available

You should take repaglinide tablets orally before each meal, anytime from 30 minutes before a meal to just before the meal. If you skip a meal, skip the dose of repaglinide. If you add an extra meal, take an extra dose of repaglinide. Your doctor may gradually adjust your dose based on your response to the medication. 

Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any parts you do not understand. Take repaglinide exactly as directed—do not take more or less than instructed or more frequently than advised by the package label or your doctor.

Continue taking repaglinide even if you feel well, and do not stop taking it without consulting your doctor.

Warnings, Precautions and Side Effects of undefined

Warnings

Repaglinide can cause severe low blood sugar, particularly if patients skip meals or increase their exercise. Use Repaglinide with caution in individuals with liver issues, as the liver metabolises the drug and dose adjustments may be necessary. Be aware that some medications can affect the effectiveness of Repaglinide or heighten the risk of hypoglycemia. During pregnancy, use Repaglinide only if required, and consult a doctor if breastfeeding.

Precautions

  • Monitor blood glucose levels: Regularly check blood glucose levels to avoid hypoglycemia.
  • Adjust dosage in hepatic impairment: Adjust the dose for patients with liver dysfunction, as the liver metabolises Repaglinide.
  • Consider drug interactions: Be cautious with drugs that can affect Repaglinide's effectiveness or increase the risk of low blood sugar.
  • Use with caution in renal impairment: Monitor and adjust the dose for patients with kidney problems.
  • Avoid in pregnancy unless necessary: Use Repaglinide during pregnancy only if the benefits outweigh the risks and consult healthcare professionals.
  • Monitor for allergic reactions: Watch for signs of serious allergic reactions, such as rash, itching, or swelling.

Side Effects

Common side effects of repaglinide include: 

  • Low blood sugar
  • Weight gain

Serious side effects of repaglinide are:

  • Allergic reactions
  • Liver problems
  • Rare cases of anaemia, thrombocytopenia, or leukopenia.

Word Of Advice

Inform your doctor of any liver or kidney issues and monitor your blood glucose levels regularly to prevent hypoglycemia. Report any symptoms of low blood sugar and inform your provider of all other medications you take to avoid interactions. Use Repaglinide during pregnancy only if essential, and watch for allergic reactions, reporting any issues immediately.

Frequently Asked Question

References

  1. Christoph Hasslacher, for the Multinational Repaglinide Renal Study Group; Safety and Efficacy of Repaglinide in Type 2 Diabetic Patients With and Without Impaired Renal Function. Diabetes Care 1 March 2003; 26 (3): 886–891.https://doi.org/10.2337/diacare.26.3.886
  2. https://www.ema.europa.eu/en/documents/product-information/prandin-epar-product-information_en.pdf
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020741s041s042lbl.pdf

Disclaimer

The drug information on this page is not a substitute for medical advice; it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.